ORPOF Stock Chart & Stats
$4.43
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$4.43 - $11.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$73.52M
Enterprise Value$102.63M
Total Cash (Recent Filing)$22.65M
Total Debt (Recent Filing)$35.38M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Sep 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding23,560,110
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.20
Price to Sales (P/S)43.87
P/FCF Ratio-3.37
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue39.19
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.39
Revenue Forecast (FY)$7.15M
Bulls Say, Bears Say
Bulls Say
Immunotherapy PipelineA pipeline spanning immuno-oncology and immuno-inflammation gives OSE exposure to multiple therapeutic markets and development opportunities. Clinical and preclinical programs can support continued value creation if candidates advance, while the focused platform builds expertise around immune-system modulation.
Partnering-Based Business ModelCollaboration and licensing can extend OSE’s development reach beyond its 64-employee base and provide access to larger partners’ resources. Potential upfront, research, milestone, and royalty payments also create routes to fund innovation without relying solely on product sales.
Improved Leverage Versus 2023Although current leverage remains material, improvement from the more leveraged 2023 position indicates some balance-sheet repair over the period. This provides a modest foundation for financial resilience, provided the company can prevent further losses from eroding equity.
Bears Say
Revenue Collapse And LossesThe sharp fall in revenue and return to heavy losses show that earnings depend on unstable development or collaboration outcomes rather than a predictable commercial base. Persistently weak revenue would limit internal funding capacity and make recovery dependent on future program progress or financing.
Significant Cash BurnA swing from approximately €48.4M of positive operating and free cash flow in 2024 to roughly €34M of burn in 2025 materially reduces financial flexibility. If negative cash generation continues, OSE may need additional funding to sustain research and clinical development.
Debt Exceeds EquityDebt exceeding equity leaves a relatively thin capital cushion for a company reporting substantial losses and cash burn. Continued equity erosion could increase funding pressure, constrain strategic choices, and make the balance sheet more vulnerable if development spending remains high.
OSE Immunotherapeutics SA News
ORPOF FAQ
What was OSE Immunotherapeutics SA’s price range in the past 12 months?
OSE Immunotherapeutics SA lowest stock price was $4.43 and its highest was $11.60 in the past 12 months.
What is OSE Immunotherapeutics SA’s market cap?
OSE Immunotherapeutics SA’s market cap is $73.52M.
When is OSE Immunotherapeutics SA’s upcoming earnings report date?
OSE Immunotherapeutics SA’s upcoming earnings report date is Sep 28, 2026 which is in 13 days.
How were OSE Immunotherapeutics SA’s earnings last quarter?
OSE Immunotherapeutics SA released its earnings results on Apr 30, 2026. The company reported -$1.164 earnings per share for the quarter.
Is OSE Immunotherapeutics SA overvalued?
According to Wall Street analysts OSE Immunotherapeutics SA’s price is currently Undervalued.
Does OSE Immunotherapeutics SA pay dividends?
OSE Immunotherapeutics SA does not currently pay dividends.
What is OSE Immunotherapeutics SA’s EPS estimate?
OSE Immunotherapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OSE Immunotherapeutics SA have?
OSE Immunotherapeutics SA has 23,560,110 shares outstanding.
What happened to OSE Immunotherapeutics SA’s price movement after its last earnings report?
OSE Immunotherapeutics SA reported an EPS of -$1.164 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of OSE Immunotherapeutics SA?
Currently, no hedge funds are holding shares in ORPOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OSE Immunotherapeutics SA
Based in Nantes, France, OSE Immunotherapeutics S.A. specializes in creating immunotherapies designed to activate or regulate the immune system. Their work primarily targets both immuno-oncology and autoimmune diseases. Their advanced pipeline features Tedopi, which is currently in Phase III clinical trials for non-small cell lung cancer, with further Phase II investigations ongoing for pancreatic and ovarian cancers. For infectious diseases, they are developing CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus. In oncology, their portfolio also includes BI 765063, in Phase I for solid tumors, and BiCKI, an innovative bispecific checkpoint inhibitor platform. BiCKI is engineered to counteract cancer's primary and secondary resistance mechanisms by targeting PD-1 alongside other novel pathways. Addressing autoimmune and inflammatory conditions, OSE Immunotherapeutics is progressing OSE-127, a humanized monoclonal antibody in Phase II trials for both ulcerative colitis and Sjögren's Syndrome. FR104 is undergoing Phase I development for rheumatoid arthritis, while OSE-230, an agonist antibody against ChemR23, aims to resolve chronic inflammation. The company maintains strategic collaborations and partnerships with organizations such as GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. OSE Immunotherapeutics S.A. was formerly known as OSE Pharma SA until its name change in May 2016.